Navigation Links
New MedPredict Report Suggests Market for Alcoholism Therapies is Underestimated
Date:4/3/2008

SCOTTSDALE, Ariz., April 3, 2008 /PRNewswire/ -- In this report, entitled "MedPredict Thought Leader Insight & Analysis: Pharmacotherapies for Alcoholism," physician experts discuss the key controversies surrounding development of drugs for alcoholism, and why they think the biopharmaceutical industry is underestimating the size of this market.

According to this physician panel, there are a number of factors stymieing biopharmaceutical companies, including the lackluster commercial performance of naltrexone and acamprosate, a lack of clear FDA guidance on trial design and resulting indications, the stigma associated with alcoholism and associated corporate image risks, and the tremendous fear of product liability litigation. The general corporate perception is that drugs for alcoholism won't be reimbursable, and many of the people who come in for treatment will not be able to afford medicine.

"An analogy would be to attempt to forecast the size of the antidepressant market before the availability of Prozac," according to Dr. Jeff Berk, the report's principal author. "While competitive intensity in the alcoholism field has been low by traditional measures, it is clearly now emerging. We expect to see tremendous growth after the first successful product launches into the primary care physician's office."
Also addressed by MedPredict's panel:

-- Unmet needs from the patient, specialist, general practitioner,

3rd-party payer and societal perspective,

-- Habits & practices of specialists, general practitioners and

non-medical treaters,

-- Hurdles preventing increased diagnosis and treatment of alcoholism,

particularly in the community setting, and a commercialization model

that Pharma can follow to overcome these,

-- Changing paradigms in primary and secondary clinical trial endpoints

and alcoholism trial designs, and

-- New screening tools and behavioral diagnostic instruments.

Drugs/classes mentioned in this report: ReVia (naltrexone); Vivitrol (extended release injectable naltrexone; Alkermes / Cephalon); Campral (acamprosate; Forest); Antabuse (disulfiram); gabapentin (generic); Topamax (topiramate; Ortho-McNeil); Prometa (flumazanil / gabapentin / hydroyzine; Hythiam); glutamatergic; non-NMDA; kainate; AMPA; CB-1; Acomplia (rimonabant; Sanofi-Aventis); SSRI; dopaminergic; Seroquel (quetiapine; AstraZeneca); NPY; NK; CRH.

About MedPredict

MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pipeline for Lung Cancer Therapies is Focus of New MedPredict Report
2. Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. QMed, Inc. Reports July Medicare SNP Enrollments
5. Phlo Affiliate Reports Expanded Coverage to Oregon Border
6. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... They call it the “hairy ball.” ... depiction of a system of linkages and connections so complex and dense that ... computer science at Worcester Polytechnic Institute (WPI) and director of the university’s bioinformatics ...
(Date:10/12/2017)... ... ... AMRI, a global contract research, development and manufacturing organization ... quality of life, will now be offering its impurity solutions as a stand-alone ... for all new drug products, including the finalization of ICH M7 earlier this ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ComplianceOnline’s Medical ... place on 7th and 8th June 2018 in San Francisco, CA. The Summit brings ... well as several distinguished CEOs, board directors and government officials from around the world ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new study published in ... and fresh in vitro fertilization (IVF) transfer cycles. The multi-center matched ... , After comparing the results from the fresh and frozen transfer cohorts, the ...
Breaking Biology Technology:
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
(Date:4/4/2017)... --  EyeLock LLC , a leader of iris-based identity ... and Trademark Office (USPTO) has issued U.S. Patent No. ... iris image with a face image acquired in sequence ... th issued patent. "The issuance ... multi-modal biometric capabilities that have recently come to market ...
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
Breaking Biology News(10 mins):